Anixa Biosciences Receives Breast Cancer Vaccine IND Transfer from Cleveland Clinic

Cleveland Clinic has transferred its breast cancer vaccine IND to Anixa Biosciences. The vaccine is designed to target triple-negative breast cancer and other breast cancers that express the α-lactalbumin protein. Anixa will now be responsible for further development of the vaccine. The transfer is a significant milestone for Anixa, which is focused on the treatment and prevention of cancer through its therapeutic portfolio.